SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies.

Therapeutic mAbs and bi- and tri-specific antibodies target no more than three epitopes, and their Fc domains define and limit whether or how they modulate complement, cellular immune responses and other immune system features. By contrast, “the polyclonal response is already suited very well for activation of the entire immune system,” Eddie Sullivan, co-founder, president and CEO of SAB Biotherapeutics Inc., told BioCentury...